Skip to main content
Biohit Oyj logo

Biohit Oyj — Investor Relations & Filings

Ticker · BIOBV ISIN · FI0009005482 LEI · 74370089ATTSNBXJVT29 HE Manufacturing
Open in API
Filings indexed 992 across all filing types
Latest filing 2024-03-20 Remuneration Information
Country FI Finland
Listing HE BIOBV

About Biohit Oyj

https://www.biohithealthcare.com/en/

Biohit Oyj is a global biotechnology company that develops, manufactures, and markets innovative diagnostic products and services. The company specializes in tools for the early diagnosis and prevention of diseases, with a primary focus on gastroenterology. Its key offerings include the GastroPanel® blood test for assessing stomach health and screening for risks of gastric cancer, as well as diagnostic tests for conditions such as Helicobacter pylori infection. Operating under the mission "Innovating for Health," Biohit's products are designed to support medical research, facilitate early and accurate diagnosis, and improve patient quality of life.

Recent filings

Filing Released Lang Actions
Publication of Biohit Oyj Remuneration Report 2023
Remuneration Information Classification · 98% confidence The document is explicitly titled "REMUNERATION REPORT 2023". It details the compensation structure, fees, bonuses, and share-based incentives for the Board of Directors and the CEO, comparing them against financial performance over several years. This content directly aligns with the definition of a Remuneration Information report, which corresponds to the DEF 14A code in the provided schema, even though the Finnish Corporate Governance Code is mentioned as the preparation standard. Since the document is a full report detailing compensation rather than just an announcement of one, DEF 14A is the most appropriate classification.
2024-03-20 English
Publication of Biohit Oyj Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'VUOSIKERTOMUS 2023' which translates to 'Annual Report 2023' in Finnish. It contains detailed sections typical of an annual report such as CEO review, strategy, governance, financial statements, key financial figures for the year 2023, and comprehensive business and operational information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely a notice or a certification. The content includes financial performance, strategy, governance, and operational details consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-20 Finnish
Publication of Biohit Oyj Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'VUOSIKERTOMUS 2023' (Annual Report 2023) for Biohit Oyj. It contains comprehensive sections including a CEO review, strategy, governance report, and financial statements (Tilinpäätös) with key performance indicators for the fiscal year 2023. It is a full annual report document, not an announcement or a summary. FY 2023
2024-03-20 Finnish
Publication of Biohit Oyj Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2023' and contains comprehensive sections typical of an annual report, including CEO's review, strategy, corporate governance, financial statements, and detailed financial data for the year 2023. It includes a full table of contents, detailed financial figures, management discussion, and corporate governance statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement of the report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-03-20 English
Publication of Biohit Oyj Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2023' and contains comprehensive sections including a CEO's review, strategy, corporate governance, and detailed financial statements (e.g., revenue, EBITDA, profit/loss). It is a full-length annual report covering the company's yearly performance, which aligns with the definition of a 10-K (Annual Report). FY 2023
2024-03-20 English
BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2023
Earnings Release Classification · 98% confidence The document is titled "BIOHIT-KONSERNIN TILINPÄÄTÖSTIEDOTE 2023" (Biohit Group Financial Statement Release 2023) and provides detailed financial summaries for the period January-December 2023, including revenue, operating profit, balance sheet data, cash flow, and management commentary on the full year's performance. This structure, containing comprehensive annual financial figures and management discussion, strongly indicates a full-year financial report. Although the title uses the Finnish term for 'Financial Statement Release,' which might sometimes align with an Earnings Release (ER) or Interim Report (IR), the scope covers the entire fiscal year (1-12/2023) and includes detailed balance sheet and operational reviews, making it equivalent to a comprehensive Annual Report (10-K in US context, or a detailed annual filing in other jurisdictions). Given the options, the most appropriate classification for a comprehensive annual financial report is 10-K, as it covers the full year's activity and performance. FY 2023
2024-02-14 Finnish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.